Help us: Donate
Follow us on:
×

Menu

Back

Month: November 2019

DNA clock
A team of researchers, including Drs. Vadim Gladyshev and Steve Horvath, recently published a review of DNA methylation aging clocks, which use biomarkers to determine the biological age of a person. Aging causes epigenetic alterations to occur, including changes to DNA methylation, histone modification, transcriptional alterations (variance in gene expression), and remodeling of chromatin (a...
Open doors
As many of you recover from enjoying Thanksgiving, we want to give a small update to the people we are most thankful to: our monthly patrons, the Lifespan Heroes. Without the continued support of the Heroes, quite simply, we could not continue to do the work we do; we could not report on the latest...
For the November episode of the Journal Club, Dr. Oliver Medvedik reviewed a new study from a team of researchers including Professor George Church. The study saw the deployment of a multiple target gene therapy focused on 3 known longevity genes delivered via an adeno-associated virus. The focus was on mitigating T2 diabetes, heart failure, and kidney failure...
X10 EARD2019
Aimed at people who aren't familiar with our annual Ending Age-Related Diseases conference, this video showcases this year's speakers, getting their thoughts and perspectives on where we are now and what can be done about aging in the future. HELP SPREAD THE WORD Please connect with us on social media, like and share our content,...
Rapamycin skin
The results of a small human clinical trial focused on skin aging have been published, and they are positive. A topical application of rapamycin, an FDA-approved drug that is used to combat organ rejection during donor transplants and targets the mechanistic target of rapamycin (mTOR) pathway, was tested to see if it had any effect...
Colombia
Recently, Libella Gene Therapeutics has announced that it will be running a patient-paid trial in Colombia with an eye-watering $1 million USD price tag on enrollment. Patient-paid trial likely to cause backlash The topic of patient-paid trials often stirs up considerable debate among the research community, regulatory authorities, and the general public, with many people...